Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$36.31 +1.0%	$33.92	$21.62 ▼ $39.47	$6.89B	1.08	2.27 million shs	1.29 million shs
CNTA Centessa Pharmaceuticals	$13.79 +1.3%	$14.42	$7.75 ▼ $19.09	$1.84B	1.53	605,883 shs	480,936 shs
LEGN Legend Biotech	$34.28 +0.1%	$34.76	$29.27 ▼ $60.87	$6.30B	0.21	1.23 million shs	570,668 shs
TGTX TG Therapeutics	$41.33 +2.6%	$37.18	$12.93 ▼ $43.32	$6.56B	2.14	3.09 million shs	1.46 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+1.90%	+6.17%	-2.12%	-4.34%	+43.67%
CNTA Centessa Pharmaceuticals	+4.45%	+10.65%	-13.92%	-17.31%	+43.87%
LEGN Legend Biotech	-0.17%	+4.39%	-2.31%	-7.23%	-24.20%
TGTX TG Therapeutics	+1.91%	+5.17%	-5.84%	+28.92%	+188.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5767 of 5 stars	4.5	2.0	3.9	2.6	4.2	0.6
CNTA Centessa Pharmaceuticals	3.066 of 5 stars	3.5	3.0	0.0	2.9	3.3	0.6
LEGN Legend Biotech	2.2168 of 5 stars	3.5	2.0	0.0	2.6	1.7	0.6
TGTX TG Therapeutics	3.4014 of 5 stars	1.4	3.0	3.5	3.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$53.00	45.97% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.71	100.97% Upside
LEGN Legend Biotech	2.92	Moderate Buy	$78.82	129.92% Upside
TGTX TG Therapeutics	2.83	Moderate Buy	$40.67	-1.60% Downside

Current Analyst Ratings Breakdown

Latest CNTA, BBIO, LEGN, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	LEGN Legend Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/31/2025	BBIO BridgeBio Pharma	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/24/2025	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $50.00
3/17/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$82.00 ➝ $80.00
3/12/2025	LEGN Legend Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/12/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $75.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	31.07	N/A	N/A	($7.71) per share	-4.71
CNTA Centessa Pharmaceuticals	$6.85M	268.00	N/A	N/A	$2.42 per share	5.70
LEGN Legend Biotech	$627.24M	10.04	N/A	N/A	$6.88 per share	4.98
TGTX TG Therapeutics	$329.00M	19.95	$0.12 per share	353.90	$1.06 per share	38.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$2.85	N/A	N/A	N/A	-241.44%	N/A	-75.69%	4/29/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.99	N/A	N/A	N/A	N/A	-52.13%	-38.01%	5/12/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.48	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	5/12/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.14	N/A	41.33	N/A	-5.42%	-8.32%	-3.40%	4/29/2025 (Estimated)

Latest CNTA, BBIO, LEGN, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	LEGN Legend Biotech	-$0.34	N/A	N/A	N/A	$190.83 million	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	N/A	N/A	N/A	$117.07 million	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$0.90	N/A	N/A	N/A	$57.14 million	N/A
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million
2/20/2025	Q4 2024	BBIO BridgeBio Pharma	-$1.09	-$1.31	-$0.22	-$1.40	$4.04 million	$5.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
LEGN Legend Biotech	0.27	4.98	4.90
TGTX TG Therapeutics	1.27	4.59	3.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
CNTA Centessa Pharmaceuticals	82.01%
LEGN Legend Biotech	70.89%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	24.66%
CNTA Centessa Pharmaceuticals	11.59%
LEGN Legend Biotech	0.02%
TGTX TG Therapeutics	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.86 million	143.29 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.18 million	116.56 million	Optionable
LEGN Legend Biotech	1,070	183.65 million	182.60 million	Optionable
TGTX TG Therapeutics	290	158.78 million	139.32 million	Optionable

CNTA, BBIO, LEGN, and TGTX Headlines

Recent News About These Companies

Hood River Capital Management LLC Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25 at 7:25 AM | marketbeat.com

XTX Topco Ltd Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25 at 4:01 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Barclays PLC

April 25 at 3:51 AM | marketbeat.com

Guggenheim Capital LLC Sells 14,905 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 24 at 4:23 AM | marketbeat.com

481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.

April 23 at 3:49 AM | marketbeat.com

Russell Investments Group Ltd. Purchases 26,506 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 23 at 3:32 AM | marketbeat.com

TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough

April 23 at 1:59 AM | seekingalpha.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by MYDA Advisors LLC

April 22 at 6:11 AM | marketbeat.com

Altium Capital Management LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 20, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Invesco Ltd.

April 20, 2025 | marketbeat.com

Legal & General Group Plc Sells 7,065 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 19, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Wells Fargo & Company MN

April 19, 2025 | marketbeat.com

EAM Investors LLC Decreases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 18, 2025 | marketbeat.com

TG Therapeutics: Progress In MS Tempered By High Expectations

April 17, 2025 | seekingalpha.com

Federated Hermes Inc. Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 15, 2025 | marketbeat.com

Franklin Resources Inc. Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 15, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Alliancebernstein L.P.

April 15, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Wellington Management Group LLP

April 15, 2025 | marketbeat.com

O Shaughnessy Asset Management LLC Takes $259,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 14, 2025 | marketbeat.com

Geode Capital Management LLC Sells 11,723 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 13, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Shares Down 11.8% - Here's What Happened

April 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA, BBIO, LEGN, and TGTX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$36.31 +0.35 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$36.78 +0.47 (+1.31%)

As of 07:34 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.79 +0.18 (+1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$13.95 +0.16 (+1.16%)

As of 06:29 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Legend Biotech NASDAQ:LEGN

$34.28 +0.04 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$34.44 +0.16 (+0.45%)

As of 06:57 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

TG Therapeutics NASDAQ:TGTX

$41.33 +1.03 (+2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$41.42 +0.09 (+0.23%)

As of 07:58 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time